A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions

Healthy

Interventions

DRUG

Seltorexant

Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.

Trial Locations (1)

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY